#United States #San Francisco #Prader-Willi Syndrome #Aardvark Therapeutics #ARD-101

Aardvark Therapeutics Under Pressure Due to Significant Stock Plunge

On March 2, 2026, Aardvark Therapeutics (NASDAQ: AARD) shocked investors when it announced a pause on its Phase 3 trial known as the Hunger Elimination of Reduction Objective (HERO). This trial was meant to assess the efficacy and safety of ARD-101 for treating hyperphagia, a condition characterized by insatiable hunger, particularly in patients diagnosed with Prader-Willi Syndrome (PWS). Following this announcement, Aardvark shareholders saw their investments plummet by $7.02, marking a staggering 56% drop in the company's stock value.

The abrupt halt in the HERO trial was attributed to serious safety concerns, specifically relating to what were described as reversible cardiac observations. Investors, already under pressure, were further dismayed by the news that the long-anticipated topline data from this trial would not be provided as previously expected during the third quarter of 2026.

Given the dramatic market reaction to this development, the law firm Hagens Berman Sobol Shapiro LLP has launched an investigation aimed at determining whether Aardvark misled investors regarding critical safety and efficacy information concerning ARD-101, and whether proper disclosures were made in their communications with the FDA. This inquiry is particularly crucial for investors who may have faced substantial financial losses as a result of the company's announcements.

Background on ARD-101 and Its Development

Aardvark Therapeutics had previously positioned ARD-101 as a pioneering treatment, one that could revolutionize how hyperphagia is managed among patients with PWS. The firm had communicated that it had developed a favorable relationship with the FDA, initially beginning trials on adolescents aged 13 years and older and showing intentions to include even younger patients in the future. Aardvark had confidently assured investors that ARD-101 came with a ''very tolerable safety profile.''

This confidence, however, was shattered when the clinical trial was suddenly placed on hold, triggering a collapse in investor trust. Analysts promptly revised their expectations for the company's stock, estimating considerable reductions or complete suspensions of price targets as new safety signals emerged.

Investigative Efforts and Responses

As a part of their investigation, Hagens Berman is focusing on the communications surrounding ARD-101's safety data, delving into whether Aardvark had adequately informed investors and the public about potential risks associated with the drug. Partner Reed Kathrein, who is leading the inquiry, emphasized, “We are keen to ascertain whether Aardvark may have misled investors about ARD-101's development trajectory and its communications with federal regulators.”

Aardvark investors who have suffered significant losses during this tumultuous time are being urged to document and report their losses proactively. Additionally, individuals with knowledge of Aardvark Therapeutics or its medications are encouraged to come forward to assist in the ongoing investigation.

The Path Ahead for Investors

For investors affected by these recent developments, there are actions that can be taken. Many are advised to consult with legal counsel specializing in securities issues, particularly those related to potential corporate misconduct. Moreover, whistleblowers bearing non-public information about Aardvark Therapeutics are encouraged to report their findings, potentially benefiting from the SEC Whistleblower Program that offers substantial rewards for information leading to successful recovery efforts.

Conclusion

The situation surrounding Aardvark Therapeutics remains fluid as the company navigates significant legal scrutiny and investor dissatisfaction. It will be crucial for both the firm and its investors to stay updated on developments in the investigation while addressing the underlying concerns regarding the safety and efficacy of ARD-101. As the landscape continues to shift, it reflects the growing challenges many biotech firms face in maintaining investor confidence amidst clinical uncertainties.